Sarissa Capital Management LP's Q3 2026 13F: 1 position resized, no new positions or exits

Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 10 reported positions · accession 0001420506-26-002892

What changed this quarter

Sarissa Capital Management LP's changes in reported equity positions, Q3 2026
Activity Security Weight before Weight now Change Shares Shares %
Reduced AMARIN CORP PLC (AMRN) 15.0% 10.9% −4.1 pts −386K sh −23%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

No changes in the top 10 this quarter

# Security Weight before Weight now
1 INNOVIVA INC (INVA) 24.1% 26.2%
2 IRONWOOD PHARMACEUTICALS INC (IRWD) 21.7% 23.8%
3 AMARIN CORP PLC (AMRN) 15.0% 10.9%
4 LANTHEUS HLDGS INC (LNTH) 10.4% 10.8%
5 NEUROCRINE BIOSCIENCES INC (NBIX) 11.0% 10.8%
6 CYTOKINETICS INC (CYTK) 10.9% 9.8%
7 BIOHAVEN LTD (BHVN) 4.9% 5.1%
8 REGENERON PHARMACEUTICALS (REGN) 1.5% 2.1%
9 VOR BIOPHARMA INC (VOR) 0.3% 0.3%
10 BIOGEN INC (BIIB) 0.1% 0.1%

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).